Reviewing the process intensification landscape through the introduction of a novel, multitiered classification for downstream processing
Crowley, Louis, Cashen, Paul, Noverraz, Marc, Lobedann, Martin, Nestola, Piergiuseppe
Published in Biotechnology and bioengineering (01.03.2024)
Published in Biotechnology and bioengineering (01.03.2024)
Get full text
Journal Article
Manufacturing a chimpanzee adenovirus‐vectored SARS‐CoV‐2 vaccine to meet global needs
Joe, Carina C. D., Jiang, Jinlin, Linke, Thomas, Li, Yuanyuan, Fedosyuk, Sofiya, Gupta, Gaurav, Berg, Adam, Segireddy, Rameswara R., Mainwaring, David, Joshi, Amar, Cashen, Paul, Rees, Byron, Chopra, Nitin, Nestola, Piergiuseppe, Humphreys, Jonathan, Davies, Sarah, Smith, Nick, Bruce, Scott, Verbart, Dennis, Bormans, Daan, Knevelman, Carol, Woodyer, Mark, Davies, Lee, Cooper, Lisa, Kapanidou, Maria, Bleckwenn, Nicole, Pappas, Daniel, Lambe, Teresa, Smith, Daniel C., Green, Catherine M., Venkat, Raghavan, Ritchie, Adam J., Gilbert, Sarah C., Turner, Richard, Douglas, Alexander D.
Published in Biotechnology and bioengineering (01.01.2022)
Published in Biotechnology and bioengineering (01.01.2022)
Get full text
Journal Article
Addressing Performance, Scalability, and Regulatory Challenges to Accelerate Cell Therapy Manufacturing: To date, the FDA has approved 36 cell and gene therapy products (1). In the past decade, new cell therapy modalities such as chimeric antigen receptor T-cell (CAR-T) immunotherapies have emerged as promising treatments especially for many types of cancers. There are now six FDA approved commercially available CAR-T products (2) and the development of cell therapies is continuing to gather pac
Get full text
Magazine Article